Drug intelligence / Profile preview

Varicella-zoster virus mRNA vaccine

Development stage
Unknown
Lead developer
Walvax Biotechnology
Modality
Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular
01

Overview

The Varicella-zoster virus mRNA vaccine is an investigational vaccine candidate developed by Walvax Biotechnology utilizing messenger RNA (mRNA) technology. It is designed to prevent infections caused by the varicella-zoster virus (VZV), which is responsible for both varicella (chickenpox) and herpes zoster (shingles). The vaccine works by introducing mRNA that encodes for a specific VZV antigen into the body, prompting host cells to produce the viral protein and subsequently triggering a robust immune response, including the production of neutralizing antibodies and the activation of T-cells. This approach aims to provide long-lasting protection against VZV reactivation and associated complications. As of early 2024, the vaccine is in Phase 1 clinical trials to assess its safety and immunogenicity profile.

Other names
VZV mRNA vaccineWalvax VZV mRNA vaccine

Beyond the preview

Go deeper on Varicella-zoster virus mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Varicella-zoster virus mRNA vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call